Company intelligence / Profile preview

VisVires New Protein

Singapore, Singapore

Ownership: Private
Employees: ~4
Development stage: Other

Overview

VisVires New Protein, now known as Clay Capital, is an agrifood venture capital firm that invests in startups addressing food system challenges related to sustainable production, livestock diseases, and antibiotic resistance. They manage a $145M second fund and focus on areas like sustainable packaging, fermentation, agriculture biologicals, crop disease resistance, soil health, and regenerative agriculture.

Industry: Investors

Beyond the preview

Go deeper on VisVires New Protein.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VisVires New Protein.

Explore the full profile